trump medicare glp 1 President announced that will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management indications for people with obesity. Our senior staff writer Kristen Monaco breaks it down on the latest Trump says GLP-1 weight-loss drugs

You might also find that your skin looks dull or that you take longer to recover from physical exercise

The TRIUMPH-4 Phase 3 data provides the most current safety information: Nausea: 38.1% (9 mg) to 43.2% (12 mg) versus 10.7% placebo Diarrhea: 34.7% (9 mg) to 33.1% (12 mg) versus 13.4% placebo Constipation: 21.8% (9 mg) to 25.0% (12 mg) versus 8.7% placebo Vomiting: 20.4% (9 mg) to 20.9% (12 mg) versus 0% placebo Decreased appetite: 19.0% (9 mg) to 18.2% (12 mg) versus 9.4% placebo The pattern is clear

Addiction Recovery: NAD+ therapy has shown promise in alleviating withdrawal symptoms and restoring brain function in individuals recovering from substance abuse

Gami AS, Somers VK

When and how to treat acute hepatitis C

MihalasBPDeIuiis GNRedgroveKAMcLaughlinEANixonB